Selinexor + Bortezomib + Dexamethasone

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
69
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Multiple Myeloma

Conditions

Multiple Myeloma

Trial Timeline

May 24, 2017 โ†’ May 12, 2022

About Selinexor + Bortezomib + Dexamethasone

Selinexor + Bortezomib + Dexamethasone is a phase 3 stage product being developed by Karyopharm Therapeutics for Multiple Myeloma. The current trial status is completed. This product is registered under clinical trial identifier NCT03110562. Target conditions include Multiple Myeloma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03110562Phase 3Completed